ClickCease

Episode 2: Notes from the Forefront of Regenerative Medicine (Part 1)

Dr. Anand Srivastava | Co-Founder, Chairman GIOSTAR | GIOTalk

Episode Summary

This installment of GIOTalk features a helpful overview of Dr. Anand Srivastava's ground-breaking discoveries in the field of stem cell research, along with his views on the future of regenerative medicine.

About Our Guest

GIOSTAR was founded with the goal of “delivering the most advanced, expensive, and elite science to the masses” by Dr. Anand Srivastava and Deven Patel. For more than two decades, “Dr. Anand” (as he is known by colleagues) has played an integral role in developing stem cell research programs at University of California San Diego (UCSD), Salk Institute of Biological Studies, and several other leading institutions.

Dr. Anand Srivastava boasts several accomplishments, including:

  • sequencing of more than 20 genes in the Japanese flounder, to better understand genetic evolution of mammals
  • demonstration in the lab of the potential of generating blood cells from stem cells – a finding that may assist in the development of treatment for several blood-related diseases

He has received numerous accolades for his ground-breaking research, including “Best in Business” Certificate of Recognition, and the Japan International Science and Technology Exchange Center (JISTEC) Award.

For a more in-depth understanding of Dr. Anand’s background, please visit his bio page

Written by GIOSTAR Chicago

GIOSTAR Chicago offers cutting-edge regenerative medicine techniques and protocols that have been extensively researched and developed by our leading scientists. Our team consists of world-renowned authorities in stem cell biology, protein biochemistry, molecular biology, immunology, in utero transplantation of stem cell, tissue targeting, gene therapy and clinical research. GIOSTAR Chicago physicians are highly-credential health care professionals, offering personalized patient care to patients suffering from a broad range of degenerative diseases.